Hemophilia A patients (n=19) switched from standard half-life (SHL) factor VIII (FVIII) to weekly EHL FVIII prophylaxis, while hemophilia B patients (n=6) transitioned from on-demand SHL factor IX (FIX) to glycopegylated EHL FIX prophylaxis every 21 days. Here, F8 is linked to hemophilia B.